Affordable Access

Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.

Authors
  • Ernst, D S
  • Tannock, I F
  • Winquist, E W
  • Venner, P M
  • Reyno, L
  • Moore, M J
  • Chi, K
  • Ding, K
  • Elliott, C
  • Parulekar, W
Type
Published Article
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publication Date
Sep 01, 2003
Volume
21
Issue
17
Pages
3335–3342
Identifiers
PMID: 12947070
Source
Medline
License
Unknown

Abstract

MP provides useful palliation in symptomatic men with HRPC. Clodronate does not increase the rate of palliative response or overall quality of life. Clodronate may be beneficial to patients who have moderate pain, but this requires further confirmation.

Report this publication

Statistics

Seen <100 times